Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
29 July, 2026
TROG to run breast cancer trial in Australia after gaining $2.86m grant
LATEST NEWS: 29 July 2026 TROG Cancer Research is
21 July, 2026
New TROG Scientific Committee Chair-Elect and members bring diverse experience
LATEST NEWS: 21 July 2026 The TROG Scientific Committee